Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.

Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG.

BMC Cancer. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.

2.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
3.

Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU.

Pistone A, Durieux V, Grigoriu B, Meert AP.

J Intensive Care Med. 2019 Jun;34(6):435-448. doi: 10.1177/0885066618787788. Epub 2018 Aug 30.

PMID:
30165779
4.

[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].

Berghmans T, Grigoriu B, Sculier JP, Meert AP.

Rev Mal Respir. 2018 Feb;35(2):197-205. doi: 10.1016/j.rmr.2017.11.007. Epub 2018 Feb 1. Review. French.

PMID:
29395567
5.

Pain control in thoracic oncology.

Peeters-Asdourian C, Massard G, Rana PH, Van Houtte P, White AP, Grigoriu B, Lossignol D, Almalki M, Alexiou J, Engelholm JL, Sculier JP.

Eur Respir J. 2017 Sep 10;50(3). pii: 1700611. doi: 10.1183/13993003.00611-2017. Print 2017 Sep. Review.

6.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.

Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J, Sideris S, Holbrechts S, Lafitte JJ, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Sep;111:164-175. doi: 10.1016/j.lungcan.2017.07.026. Epub 2017 Jul 24. Review.

PMID:
28838389
7.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.

Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte JJ, Grigoriu B, Sculier C, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Sep;111:150-163. doi: 10.1016/j.lungcan.2017.07.025. Epub 2017 Jul 25. Review.

PMID:
28838388
8.

Intensive care in thoracic oncology.

Meert AP, Grigoriu B, Licker M, Van Schil PE, Berghmans T.

Eur Respir J. 2017 May 11;49(5). pii: 1602189. doi: 10.1183/13993003.02189-2016. Print 2017 May. Review.

9.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.

Bentea G, Sculier C, Grigoriu B, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Apr;106:83-92. doi: 10.1016/j.lungcan.2017.01.017. Epub 2017 Jan 30. Review.

PMID:
28285700
10.

Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.

Gamarra F, Noël JL, Brunelli A, Dingemans AC, Felip E, Gaga M, Grigoriu BD, Hardavella G, Huber RM, Janes S, Massard G, Putora PM, Sculier JP, Schnabel PA, Ramella S, Van Raemdonck D, Meert AP.

Breathe (Sheff). 2016 Sep;12(3):249-255. doi: 10.1183/20734735.009116. Review.

11.

Radiation therapy for post-operative recurrence: yes, but only for limited indications.

Subotic D, Van Schil P, Grigoriu B.

Eur Respir J. 2016 Jul;48(1):278-9. doi: 10.1183/13993003.00842-2016. No abstract available.

12.

Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.

Cernomaz AT, Macovei II, Pavel I, Grigoriu C, Marinca M, Baty F, Peter S, Zonda R, Brutsche M, Grigoriu B.

BMC Pulm Med. 2016 May 23;16(1):88. doi: 10.1186/s12890-016-0250-0.

13.

Optimising treatment for post-operative lung cancer recurrence.

Subotic D, Van Schil P, Grigoriu B.

Eur Respir J. 2016 Feb;47(2):374-8. doi: 10.1183/13993003.01490-2015. No abstract available.

14.

EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER: LOCAL EPIDEMIOLOGY AND CLINICAL IMPORTANCE.

Rusu-Cordunean F, Berlea ML, Cernomaz AT, Marinca MV, Peter S, Pavel I, Grigoriu BD.

Rev Med Chir Soc Med Nat Iasi. 2015 Oct-Dec;119(4):1031-6.

PMID:
26793845
15.

Implementing EBUS TBNA: first experience and review of literature.

Rusu-Cordunean F, Cernomaz AT, Berlea ML, Ferariu D, Grigoriu BD.

Rev Med Chir Soc Med Nat Iasi. 2015 Jan-Mar;119(1):31-7. Review.

PMID:
25970939
16.

Theragnostics--a silent revolution.

Grigoriu BD.

Rev Med Chir Soc Med Nat Iasi. 2015 Jan-Mar;119(1):7-8. No abstract available.

PMID:
25970935
17.

Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).

Franzini A, Baty F, Macovei II, Dürr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche MH.

Clin Cancer Res. 2015 Dec 1;21(23):5253-63. doi: 10.1158/1078-0432.CCR-14-3135. Epub 2015 Apr 28.

18.

Management of EGFR mutated nonsmall cell lung carcinoma patients.

Grigoriu B, Berghmans T, Meert AP.

Eur Respir J. 2015 Apr;45(4):1132-41. doi: 10.1183/09031936.00156614. Epub 2015 Feb 19. Review.

19.

The non glycanated endocan polypeptide slows tumor growth by inducing stromal inflammatory reaction.

Yassine H, De Freitas Caires N, Depontieu F, Scherpereel A, Awad A, Tsicopoulos A, Leboeuf C, Janin A, Duez C, Grigoriu B, Lassalle P.

Oncotarget. 2015 Feb 20;6(5):2725-35.

20.

Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.

Paesmans M, Grigoriu B, Ocak S, Roelandts M, Lafitte JJ, Holbrechts S, Berghmans T, Meert AP, Moretti L, Danyi S, Pasleau F, Ameye L, Van Meerhaeghe A, Sculier JP.

Eur Respir J. 2015 Feb;45(2):511-24. doi: 10.1183/09031936.00092814. Epub 2014 Dec 23. Review.

21.

[Management of extensive disease small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party].

Grigoriu B, Meert AP; European Lung Cancer Working Party.

Rev Med Brux. 2014 May-Jun;35(3):164-8. French.

PMID:
25102583
22.

[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates].

Berghmans T, Cortot A, CsToth I, Garcia C, Giner-Marco V, Grigoriu B, Holbrechts S, Lafitte JJ, Meert AP, Moretti L, Paesmans M, Remmelink M, Richez M, Roelandts M, Scherpereel A, Tulippe C, Van Houtte P, Sculier JP; European Lung Cancer Working Party.

Rev Med Brux. 2014 May-Jun;35(3):132-3. French. No abstract available.

PMID:
25102578
23.

Detection of Mycobacterium tuberculosis growth by direct microscopic observation has a lower cost, higher sensitivity and higher diagnostic value than liquid and solid media cultures.

Olaru-Peter S, Grigoriu C, Boiculese LV, Gradinaru AC, Macovei II, Diculencu D, Grigoriu B.

Indian J Med Microbiol. 2014 Jul-Sep;32(3):315-7. doi: 10.4103/0255-0857.136585.

24.

The European initiative for quality management in lung cancer care.

Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, Gaga M, Gamarra F, Grigoriu B, Hansen NC, Hubbard R, Huber RM, Jakobsen E, Jovanovic D, Konsoulova A, Kollmeier J, Massard G, McPhelim J, Meert AP, Milroy R, Paesmans M, Peake M, Putora PM, Scherpereel A, Schönfeld N, Sitter H, Skaug K, Spiro S, Strand TE, Taright S, Thomas M, van Schil PE, Vansteenkiste JF, Wiewrodt R, Sculier JP.

Eur Respir J. 2014 May;43(5):1254-77. doi: 10.1183/09031936.00106913. Epub 2014 Mar 23.

25.

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe.

Gamarra F, Boffetta P, De Ruysscher D, Felip E, Gaga M, Grigoriu B, Huber RM, Janes SM, Marquette CH, Massard G, Noel JL, Sculier JP, Meert AP.

Eur Respir J. 2013 Sep;42(3):568-71. doi: 10.1183/09031936.00094613. No abstract available.

26.

Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.

Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, Trauet J, Copin MC, Dessaint JP, Porte H, Labalette M.

BMC Cancer. 2013 Jul 2;13:324. doi: 10.1186/1471-2407-13-324.

27.

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.

J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. Review.

28.

Development of monoclonal antibodies and ELISA specific for the mouse vascular endocan.

Depontieu F, de Freitas Caires N, Gourcerol D, Giordano J, Grigoriu B, Delehedde M, Lassalle P.

J Immunol Methods. 2012 Apr 30;378(1-2):88-94. doi: 10.1016/j.jim.2012.02.009. Epub 2012 Feb 20.

PMID:
22370430
29.

Assaying for circulating osteopontin in practice: a technical note.

Constantinescu D, Vornicu M, Grigoriu C, Cozmei C, Grigoriu BD.

Eur Respir J. 2010 May;35(5):1187-8. doi: 10.1183/09031936.00160609. No abstract available.

30.

Clinical utility of diagnostic markers for malignant pleural mesothelioma.

Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A.

Monaldi Arch Chest Dis. 2009 Mar;71(1):31-8. Review. Erratum in: Monaldi Arch Chest Dis. 2009 Jun;71(2):88.

PMID:
19522163
31.

Screening for malignant mesothelioma--looking for the holy grail.

Grigoriu B, Scherpereel A.

Am J Respir Crit Care Med. 2009 May 1;179(9):851; author reply 851-852. No abstract available.

PMID:
19383930
32.

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.

33.

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.

Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A.

Clin Biochem. 2009 Jul;42(10-11):1046-50. doi: 10.1016/j.clinbiochem.2009.03.007. Epub 2009 Mar 18.

34.

Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.

Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A.

Am J Respir Crit Care Med. 2009 May 15;179(10):950-4. doi: 10.1164/rccm.200807-1125OC. Epub 2009 Feb 6.

PMID:
19201924
35.

[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].

Scherpereel A, Grigoriu BD, Astoul P.

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S183-90. French.

PMID:
18971844
36.

[Disseminated tuberculosis with severe multi- organ failure in a patient with AIDS].

Grigoriu BD, Jacobs FM, Mas AE, Prat D, Prévot S, Brivet FG.

Rev Mal Respir. 2008 Sep;25(7):853-6. French.

PMID:
18946411
37.

[New diagnostic markers for malignant pleural mesothelioma].

Grigoriu BD, Grégoire M, Chahine B, Scherpereel A.

Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576. Review. French.

38.

Loss of Endocan tumorigenic properties after alternative splicing of exon 2.

Depontieu F, Grigoriu BD, Scherpereel A, Adam E, Delehedde M, Gosset P, Lassalle P.

BMC Cancer. 2008 Jan 18;8:14. doi: 10.1186/1471-2407-8-14.

39.

Sophisticated biomarkers for community-acquired pneumonia severity asessment: gadgets or useful tools?

Brivet FG, Jacobs FM, Prat D, Grigoriu BD.

Intensive Care Med. 2008 May;34(5):975-6. doi: 10.1007/s00134-007-0982-7. Epub 2008 Jan 8. No abstract available.

PMID:
18189125
40.

Diagnostic value of soluble mesothelin in malignant mesothelioma.

Grigoriu BD, Scherpereel A.

Thorax. 2008 Jan;63(1):87-8; author reply 87. No abstract available.

PMID:
18156575
41.

[Comparative evaluation between MB/BacT system and Löwenstein-Jensen solid culture media for mycobacterial isolation].

Grigoriu BD, Grigoriu C, Cojocaru C, Mihăescu T, Diculencu D.

Pneumologia. 2007 Apr-Jun;56(2):68-72. Romanian.

PMID:
18019750
42.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

43.

Endocan expression and relationship with survival in human non-small cell lung cancer.

Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P.

Clin Cancer Res. 2006 Aug 1;12(15):4575-82.

44.

Ethical flaws in Romania's health reform.

Grigoriu BD.

Lancet. 2006 Jun 24;367(9528):2059. No abstract available.

PMID:
16798387
45.

[Pulmonary disease in dental laboratory technicians].

Thorette C, Grigoriu B, Canut E, Sobaszek A, Tonnel AB, Tillie-Leblond I.

Rev Mal Respir. 2006 Apr;23 Suppl 2:4S7-4S16. French.

PMID:
16733397
46.

Cardiac troponin level is not an independent predictor of mortality in septic patients requiring medical intensive care unit admission.

Brivet FG, Jacobs FM, Colin P, Prat D, Grigoriu B.

Crit Care. 2006 Feb;10(1):404. No abstract available.

47.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138
48.

Endocan, a new endothelial marker in human sepsis.

Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P.

Crit Care Med. 2006 Feb;34(2):532-7.

PMID:
16424738
49.

Bronchoalveolar lavage cytological alveolar damage in patients with severe pneumonia.

Grigoriu B, Jacobs F, Beuzen F, El Khoury R, Axler O, Brivet FG, Capron F.

Crit Care. 2006 Feb;10(1):R2.

50.

Accuracy of clinical presentation for differentiating bacterial from viral meningitis in adults: a multivariate approach.

Brivet FG, Ducuing S, Jacobs F, Chary I, Pompier R, Prat D, Grigoriu BD, Nordmann P.

Intensive Care Med. 2005 Dec;31(12):1654-60. Epub 2005 Oct 22.

PMID:
16244879

Supplemental Content

Loading ...
Support Center